Jean Blier

2 papers in the library · 131 citations · publishing 2020

Papers

Sort Most recent Most cited

The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Recommendations for the Use of Racemic Ketamine in Adults with Major Depressive Disorder: Recommandations Du Groupe De Travail Du Réseau Canadien Pour Les Traitements De L’humeur Et De L’anxiété (Canmat) Concernant L’utilisation De La Kétamine Racémique Chez Les Adultes Souffrant De Trouble Dépressif Majeur

The Canadian Journal of Psychiatry November 11, 2020 Jennifer Swainson, Alexander McGirr, Pierre Blier et al. 109 citations

OBJECTIVE: -methyl-d-aspartate (NMDA) receptor antagonist, has demonstrated rapid antidepressant effects in patients with TRD. The Canadian Network for Mood and Anxiety Treatments (CANMAT) convened a task force to review the evidence for efficacy and safety of racemic ketamine and to provide recommendations for its use in clinical practice. METHODS: A systematic review was conducted with...

DOI: 10.1177/0706743720970860 Ketamine Anxiety Major depressive disorder Treatment-resistant depression +5

A randomized, crossover comparison of ketamine and electroconvulsive therapy for treatment of major depressive episodes: a Canadian biomarker integration network in depression (CAN-BIND) study protocol

BMC Psychiatry June 2, 2020 J. Phillips, N. Jaworska, Elizabeth Kamler et al. 22 citations

Background Recent evidence underscores the utility of rapid-acting antidepressant interventions, such as ketamine, in alleviating symptoms of major depressive episodes (MDE). However, to date, there have been limited head-to-head comparisons of intravenous (IV) ketamine infusions with other antidepressant treatment strategies in large randomized trials. This study protocol describes an ongoing...

DOI: 10.1186/s12888-020-02672-3 Full text